Senores Pharmaceuticals · NSE: SENORES · BSE: 544319
Q2 FY26 results · Jul–Sep 2025
Senores Pharmaceuticals reported revenue from operations of ₹161.76 crore and net profit of ₹30.12 crore for Q2 FY26 (Jul–Sep 2025), on a consolidated basis.
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 161.76 | — | — | 137.99 | +17.2% |
| Other income | 5.41 | — | — | 3.36 | +61.0% |
| Total income | 167.17 | — | — | 141.35 | +18.3% |
| Profit before tax | 40.64 | — | — | 26.49 | +53.4% |
| Net profit for the period | 30.12 | — | — | 21.18 | +42.2% |
| Attributable to shareholders of the company | 32.38 | — | — | 19.73 | +64.1% |
| EPS, basic (₹) | 6.54 | — | — | 4.60 | +42.2% |
| Net margin (%) | 18.6 | — | 15.3 |
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 35.33 | — | — | 19.82 | +78.3% |
| Other income | 11.36 | — | — | 8.39 | +35.4% |
| Total income | 46.69 | — | — | 28.21 | +65.5% |
| Profit before tax | 7.65 | — | — | 3.59 | +113.1% |
| Net profit for the period | 6.43 | — | — | 2.70 | +138.1% |
| EPS, basic (₹) | 1.40 | — | — | 0.59 | +137.3% |
| Net margin (%) | 18.2 | — | 13.6 |
Consolidated
- Filed with BSE
- 06 Nov 2025, 18:19 IST
- Board meeting
- 06 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 06 Nov 2025, 18:19 IST
- Board meeting
- 06 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE